A first-in-man, double blind, placebo controlled study of the candidate therapeutic vaccine Opal-HIV-Gag(c) in HIV infected patients receiving HAART

Detalles Bibliográficos
Autores principales: Jackson, AG, Kløverpris, HN, Handley, A, Hayes, P, Gilmour, J, Atkins, M, Walker, B, Ackland, J, Sullivan, M, Goulder, P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Oral Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441710/
http://dx.doi.org/10.1186/1742-4690-9-S2-O54
_version_ 1782243356246540288
author Jackson, AG
Kløverpris, HN
Handley, A
Hayes, P
Gilmour, J
Atkins, M
Walker, B
Ackland, J
Sullivan, M
Goulder, P
author_facet Jackson, AG
Kløverpris, HN
Handley, A
Hayes, P
Gilmour, J
Atkins, M
Walker, B
Ackland, J
Sullivan, M
Goulder, P
author_sort Jackson, AG
collection PubMed
description
format Online
Article
Text
id pubmed-3441710
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34417102012-09-18 A first-in-man, double blind, placebo controlled study of the candidate therapeutic vaccine Opal-HIV-Gag(c) in HIV infected patients receiving HAART Jackson, AG Kløverpris, HN Handley, A Hayes, P Gilmour, J Atkins, M Walker, B Ackland, J Sullivan, M Goulder, P Retrovirology Oral Presentation BioMed Central 2012-09-13 /pmc/articles/PMC3441710/ http://dx.doi.org/10.1186/1742-4690-9-S2-O54 Text en Copyright ©2012 Jackson et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Oral Presentation
Jackson, AG
Kløverpris, HN
Handley, A
Hayes, P
Gilmour, J
Atkins, M
Walker, B
Ackland, J
Sullivan, M
Goulder, P
A first-in-man, double blind, placebo controlled study of the candidate therapeutic vaccine Opal-HIV-Gag(c) in HIV infected patients receiving HAART
title A first-in-man, double blind, placebo controlled study of the candidate therapeutic vaccine Opal-HIV-Gag(c) in HIV infected patients receiving HAART
title_full A first-in-man, double blind, placebo controlled study of the candidate therapeutic vaccine Opal-HIV-Gag(c) in HIV infected patients receiving HAART
title_fullStr A first-in-man, double blind, placebo controlled study of the candidate therapeutic vaccine Opal-HIV-Gag(c) in HIV infected patients receiving HAART
title_full_unstemmed A first-in-man, double blind, placebo controlled study of the candidate therapeutic vaccine Opal-HIV-Gag(c) in HIV infected patients receiving HAART
title_short A first-in-man, double blind, placebo controlled study of the candidate therapeutic vaccine Opal-HIV-Gag(c) in HIV infected patients receiving HAART
title_sort first-in-man, double blind, placebo controlled study of the candidate therapeutic vaccine opal-hiv-gag(c) in hiv infected patients receiving haart
topic Oral Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441710/
http://dx.doi.org/10.1186/1742-4690-9-S2-O54
work_keys_str_mv AT jacksonag afirstinmandoubleblindplacebocontrolledstudyofthecandidatetherapeuticvaccineopalhivgagcinhivinfectedpatientsreceivinghaart
AT kløverprishn afirstinmandoubleblindplacebocontrolledstudyofthecandidatetherapeuticvaccineopalhivgagcinhivinfectedpatientsreceivinghaart
AT handleya afirstinmandoubleblindplacebocontrolledstudyofthecandidatetherapeuticvaccineopalhivgagcinhivinfectedpatientsreceivinghaart
AT hayesp afirstinmandoubleblindplacebocontrolledstudyofthecandidatetherapeuticvaccineopalhivgagcinhivinfectedpatientsreceivinghaart
AT gilmourj afirstinmandoubleblindplacebocontrolledstudyofthecandidatetherapeuticvaccineopalhivgagcinhivinfectedpatientsreceivinghaart
AT atkinsm afirstinmandoubleblindplacebocontrolledstudyofthecandidatetherapeuticvaccineopalhivgagcinhivinfectedpatientsreceivinghaart
AT walkerb afirstinmandoubleblindplacebocontrolledstudyofthecandidatetherapeuticvaccineopalhivgagcinhivinfectedpatientsreceivinghaart
AT acklandj afirstinmandoubleblindplacebocontrolledstudyofthecandidatetherapeuticvaccineopalhivgagcinhivinfectedpatientsreceivinghaart
AT sullivanm afirstinmandoubleblindplacebocontrolledstudyofthecandidatetherapeuticvaccineopalhivgagcinhivinfectedpatientsreceivinghaart
AT goulderp afirstinmandoubleblindplacebocontrolledstudyofthecandidatetherapeuticvaccineopalhivgagcinhivinfectedpatientsreceivinghaart
AT jacksonag firstinmandoubleblindplacebocontrolledstudyofthecandidatetherapeuticvaccineopalhivgagcinhivinfectedpatientsreceivinghaart
AT kløverprishn firstinmandoubleblindplacebocontrolledstudyofthecandidatetherapeuticvaccineopalhivgagcinhivinfectedpatientsreceivinghaart
AT handleya firstinmandoubleblindplacebocontrolledstudyofthecandidatetherapeuticvaccineopalhivgagcinhivinfectedpatientsreceivinghaart
AT hayesp firstinmandoubleblindplacebocontrolledstudyofthecandidatetherapeuticvaccineopalhivgagcinhivinfectedpatientsreceivinghaart
AT gilmourj firstinmandoubleblindplacebocontrolledstudyofthecandidatetherapeuticvaccineopalhivgagcinhivinfectedpatientsreceivinghaart
AT atkinsm firstinmandoubleblindplacebocontrolledstudyofthecandidatetherapeuticvaccineopalhivgagcinhivinfectedpatientsreceivinghaart
AT walkerb firstinmandoubleblindplacebocontrolledstudyofthecandidatetherapeuticvaccineopalhivgagcinhivinfectedpatientsreceivinghaart
AT acklandj firstinmandoubleblindplacebocontrolledstudyofthecandidatetherapeuticvaccineopalhivgagcinhivinfectedpatientsreceivinghaart
AT sullivanm firstinmandoubleblindplacebocontrolledstudyofthecandidatetherapeuticvaccineopalhivgagcinhivinfectedpatientsreceivinghaart
AT goulderp firstinmandoubleblindplacebocontrolledstudyofthecandidatetherapeuticvaccineopalhivgagcinhivinfectedpatientsreceivinghaart

Ejemplares similares